Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Cervomed Inc (CRVO)

Cervomed Inc (CRVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled Stocktwits - Wed Nov 27, 8:50AM CST

The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.

IWC : 137.77 (+0.67%)
VXF : 204.56 (-0.08%)
CRVO : 9.16 (+14.79%)
VTI : 298.14 (-0.30%)
IWM : 241.00 (+0.16%)
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia GlobeNewswire - Wed Nov 27, 6:00AM CST

CRVO : 9.16 (+14.79%)
CervoMed Announces Key Senior Leadership Appointments GlobeNewswire - Wed Nov 13, 7:00AM CST

CRVO : 9.16 (+14.79%)
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates GlobeNewswire - Tue Nov 12, 6:00AM CST

CRVO : 9.16 (+14.79%)
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup GlobeNewswire - Fri Nov 8, 8:55AM CST

CRVO : 9.16 (+14.79%)
CervoMed to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Nov 7, 7:30AM CST

CRVO : 9.16 (+14.79%)
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) GlobeNewswire - Mon Nov 4, 7:00AM CST

CRVO : 9.16 (+14.79%)
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference GlobeNewswire - Tue Oct 29, 7:00AM CDT

CRVO : 9.16 (+14.79%)
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) GlobeNewswire - Tue Oct 15, 7:00AM CDT

CRVO : 9.16 (+14.79%)
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced...

CRVO : 9.16 (+14.79%)

Barchart Exclusives

New Engine Beats Ford, General Motors, and Tesla By a Mile With 200% More Efficiency, 100% More Power, and 50% of the Cost Barchart - 46 minutes ago
The automotive industry has long been defined by a push for bigger, faster, and more efficient engines. Now, a revolutionary innovation threatens to outpace legacy giants like Ford (F) , Tesla (TSLA) , and General Motors (GM) . This groundbreaking engine technology, developed by a Kansas-based company and a Washington... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot